Please login to the form below

Not currently logged in
Email:
Password:

Dr Malte Peters joins MorphoSys

He succeeds Dr Arndt Schottelius as chief development officer

MorphoSys Dr Malte PetersGermany-based therapeutic antibodies specialist MorphoSys has appointed Dr Malte Peters as its new chief development officer, succeeding Dr Arndt Schottelius from 1 March.

Dr Peters joins MorphoSys from Sandoz, where he served as global head of clinical development in its biopharmaceuticals business unit.

Prior to this, he was Novartis' clinical head of oncology translational medicine and head of its Basel and East Hanover sites, and served as head of translational research and pharmacogenomics at Merck KGaA.

During this time he also held teaching appointments in internal medicines and biochemistry at the University of Mainz, in Germany.

Dr Gerald Möller, chairman of MorphoSys' supervisory board, said: “Dr Peters is an ideal addition to the management board of MorphoSys at this stage of the company's growth.

“Drawing on his deep operational and medical experience in oncology and immunology, he will focus his efforts on the development of our clinical and pre-clinical programmes, the most valuable assets driving out future growth.”

17th January 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics